Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- DSP Signs Agreement with Edison Pharmaceuticals of US for Mitochondrial Disease Treatments
April 2, 2013
- Gabriel Baertschi Takes Over as President of AZ K.K.
April 2, 2013
- MTPC Obtains Approval of SGLT-2 Inhibitor Canagliflozin in US
April 2, 2013
- 3 Companies’ Midterm Plans Foresee Poor Outlook for Domestic Market with “For-Reference-Only Figures,” “No Figures,” “Zero Growth”
April 2, 2013
- Mr Ninomiya Appointed as New President, Mr Mitani Exits to Become Advisor: Novartis Pharma
April 1, 2013
- Announcement: 6th annual Marketing Excellence Japan 2013 – Hilton Tokyo, May 14 – 15
April 1, 2013
- Dainippon Sumitomo Pharma Ties Up with Venture Company to Commercialize iPS Cell Therapy for Retinal Disease
April 1, 2013
- EMA Accepts Shionogi’s MAA for Ospemifene
April 1, 2013
- Asklep to Establish Joint Venture Company with US CRO ReSearch Pharmaceutical Services
April 1, 2013
- GSK's Operating Profit Down 22% in 2012 due to Cervarix Sales Drop
March 29, 2013
- Takeda Files NDA for Fixed-Dose Combination of Takepron, Low-Dose Aspirin in Japan
March 29, 2013
- Takeda Files NDAs for Cell Culture-Based New Flu Vaccines
March 29, 2013
- Shionogi Settles Crestor Lawsuit in US
March 28, 2013
- Equa Tops February Detailing Ranking in GP, HP Markets, Driven by Expanded Concurrent Use: Rep Track Survey
March 28, 2013
- First Time NDA Filed in Japan for Meningococcal Vaccine: Sanofi
March 28, 2013
- Otsuka, Lundbeck to Jointly Develop, Market Alzheimer’s Disease Drug
March 28, 2013
- AnGes Licenses Nucleic Acid Drug for Diseases Causing Lower Back Pain to Nippon Zoki in Japan
March 28, 2013
- Takeda, Novartis Rank 1st in Total Average Score with Favorable Impression on Quality of Development: IAL Survey
March 28, 2013
- Concurrent-Use Indications Approved for Trazenta: NBI, Eli Lilly Japan
March 27, 2013
- ASKA Targets Sales of 50 Billion yen in FY2015, Up 20% vs. FY2012 Outlook: 3-Year Plan
March 27, 2013
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…